NCT00234975 - Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

HIV Infection

Interventions

DRUG

Lopinavir/Ritonavir

400 mg/ 100 mg BID. Both arms use Kaletra 400/100 mg BID, plus NRTI chosen by the investigator

Trial Locations (11)

Site Reference ID/Investigator# 4118, Bayamón

Site Reference ID/Investigator# 4119, Bayamón

Site Reference ID/Investigator# 6298, Juana Díaz

Site Reference ID/Investigator# 6284, Las Piedras

Site Reference ID/Investigator# 4101, Mayagüez

Site Reference ID/Investigator# 4116, Playa de Ponce

Site Reference ID/Investigator# 4099, Ponce

Site Reference ID/Investigator# 4117, Ponce

Site Reference ID/Investigator# 4086, Rio Piedras

Site Reference ID/Investigator# 4080, San Juan

Site Reference ID/Investigator# 4100, Santurce

All Listed Sponsors

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY